Omeros (OMER) Short term Debt (2011 - 2025)

Omeros (OMER) reported Short term Debt of $17.1 million for Q4 2025, down 36.64% sequentially from $26.9 million in Q1 2025.

Omeros (OMER) Short term Debt (2011 - 2025) Analysis & Trends

Omeros (OMER) has 11 years of Short term Debt data on file, last reported at $17.1 million in Q4 2025.

For the quarter ending Q4 2025, Short term Debt changed N/A year-over-year to $17.1 million; the trailing twelve-month figure through Dec 2025 stood at $17.1 million (changed N/A YoY), and the FY2025 full-year result was $17.1 million, changed N/A from the prior year.
Short term Debt retreated to $17.1 million in Q4 2025, from $26.9 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $94.9 million in Q3 2023 to a low of $17.1 million in Q4 2025.
A 3-year average of $70.4 million and a median of $94.5 million in 2022 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn

Download Data